Beta Bionics prices $150M public offering of common stock and pre-funded warrants

Beta Bionics, Inc.

Priced 7,652,175 common shares at $17.25 and 1,043,484 pre-funded warrants at $17.2499 per share.
Gross proceeds expected ~$150.0M; closing expected Sept 17, 2026.
Underwriters granted 30-day option to purchase up to 1,304,348 additional shares.
Proceeds for general corporate purposes including Mint commercialization, manufacturing expansion, R&D.
J.P. Morgan, Piper Sandler, Wells Fargo, and Leerink act as joint book-running managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.